Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.
Impact of Rituximab On the Quality of Life and Physical Function of Patients with Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register.
Soliman1, Moetaza M., Hyrich2, Kimme L., Lunt2, Mark, Watson2, Kath D., Symmons2, Deborah PM, Ashcroft1, Darren M.
Improvements in the quality of life and physical function of rheumatoid arthritis (RA) patients receiving rituximab (RTX) have been shown in clinical trials. This study aimed to assess quality of life and physical function of RA patients six months after receiving RTX in routine clinical practice in the UK, and to identify factors that were associated with improvements in physical function.
The study included 448 RA patients registered with the British Society for Rheumatology Biologics Register, a national prospective cohort study, who were starting RTX and provided Health Assessment Questionnaire (HAQ) at baseline and six months after starting RTX. Changes in the HAQ scores and European Quality of life 5 Dimensions (EQ5D) ratings were used to evaluate improvements in physical function and quality of life. Multivariate regression models were used to identify factors that were associated with improvements in HAQ scores in patients receiving RTX who had failed at least one anti-tumour necrosis factor therapy. The models examined baseline demographic and disease characteristics, baseline physical function, concomitant drug therapies and previous biologic and non-biologic therapies.
Six months after starting RTX, the mean HAQ, EQ5D utility, and EQ5D visual analogue scores had significantly improved (table 1). Over one third of patients (36%) achieved the minimal clinically important difference (MCID) in HAQ (improvement of 0.22 units at least). The multivariate analysis found that high baseline HAQ score was significantly associated with an improvement in HAQ (table 2). Patients receiving concurrent steroids were significantly less likely to show an improvement in HAQ. Older patients, females, and current smokers were also significantly less likely to show either HAQ improvements or achieving MCID in HAQ.
Table 1. Six months improvements
Table 2. Significant predictors of HAQ improvements
In routine clinical practice, RTX was found to be effective in improving the quality of life and physical function of RA patients. Factors that influenced the degree of improvement in physical function included: baseline disability, smoking, concurrent use of steroids, age, and gender.
To cite this abstract, please use the following information:
Soliman, Moetaza M., Hyrich, Kimme L., Lunt, Mark, Watson, Kath D., Symmons, Deborah PM, Ashcroft, Darren M.; Impact of Rituximab On the Quality of Life and Physical Function of Patients with Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :1211